Cardiogenic Shock Clinical Trials

Find Cardiogenic Shock Clinical Trials Near You

Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this multicenter, open-label, randomized clinical trial is to learn whether norepinephrine or dopamine is more effective and safer as the first-line vasoactive drug for treating cardiogenic shock in adults. Cardiogenic shock is a life-threatening condition in which the heart cannot pump enough blood to supply the body. The main questions this study aims to answer are: Does norepinephrine reduce the risk of death or worsening cardiogenic shock compared with dopamine? Does norepinephrine lead to fewer complications such as arrhythmias, the need for mechanical circulatory support, or cardiac arrest? Researchers will compare norepinephrine and dopamine to see which drug better stabilizes blood pressure, improves tissue perfusion, and prevents progression of shock during the early phase of treatment. Participants will: Be randomly assigned to receive either norepinephrine or dopamine as the first vasoactive drug Receive treatment and monitoring based on current clinical guidelines for cardiogenic shock Undergo regular assessments of blood pressure, laboratory values, heart rhythm, and organ function during hospitalization Be followed for outcomes at 1 month, 6 months, and 1 year after enrollment This study aims to provide evidence that will help determine which initial vasoactive drug offers better outcomes for patients with cardiogenic shock and guide future treatment recommendations.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:

⁃ Age ≥ 19

⁃ Cardiogenic shock (a) in the stage of Society for cardiovascular angiography and intervention (SCAI) C or D

∙ Cardiogenic shock (a) was defined as follows, and should fulfill both 1) and 2)

⁃ systolic blood pressure \<90 mm Hg for ≥30 min or need of inotropes or vasopressors to maintain systolic blood pressure \>90 mm Hg And

• Impaired cardiac function confirmed by cardiac catheterization or echocardiography

⁃ a Cardiogenic shock was defined as follows, and should fulfill both 1) and 2)

∙ <!-- -->

⁃ systolic blood pressure \<90 mm Hg for ≥30 min or need of inotropes or vasopressors to maintain systolic blood pressure \>90 mm Hg And

• Impaired cardiac function confirmed by cardiac catheterization or echocardiography

‣ Cardiac index (CI) \< 2.2 L/min/m², measured by pulmonary artery catheter

‣ Left ventricular ejection fraction LVEF \< 45% on echocardiography;

‣ Right ventricular dysfunction, defined by one or more of: TAPSE \< 17 mm; S' \< 9.5 cm/sec; FAC \< 35%11; or visual estimation of RV wall motion abnormality.

‣ Or Structural cardiac abnormality capable of causing cardiogenic shock, even if LV/RV systolic indices do not meet the thresholds above (examples, infarct ventricular septal rupture or severe valvular regurgitation)

‣ Patients will be further classified based on the SCAI shock classification system12 as follows:

• SCAI B: no signs of hypoperfusion

• SCAI C: any signs of hypoperfusion, cardiogenic shock will be classified as SCAI C, and these include mental status change, cool and clammy skin, mottled skin appearance, decreased urine output (30ml/hour) or lactate over 2.0mmol/L

• SCAI D: shock progression despite use of the index vasoactive agent at ≥75% of the predefined maximal dose

• SCAI E: Impending arrest or overt circulatory collapse

Locations
Other Locations
Republic of Korea
Chonnam National University Hospital
RECRUITING
Gwangju
Contact Information
Primary
Min Chul Kim, Professor, MD, PhD
kmc3242@hanmail.net
820622204770
Backup
Yongwhan Lim, Professor, MD
kalmiarmfl@naver.com
820622204770
Time Frame
Start Date: 2026-06-16
Estimated Completion Date: 2032-05-31
Participants
Target number of participants: 512
Treatments
Experimental: Norepinephrine First-Line Vasoactive Drug
Participants assigned to this arm will receive norepinephrine as the first-line vasoactive drug for the treatment of cardiogenic shock. The drug will be initiated and titrated according to the protocol-defined dosing algorithm, with adjustments based on hemodynamic response, laboratory values, and clinical status. If participants were receiving vasoactive agents before randomization, norepinephrine will be started at an equivalent protocol-defined dose, and other agents will be tapered as clinically appropriate. All treatment and monitoring will follow current clinical guidelines for cardiogenic shock.
Active_comparator: Dopamine First-Line Vasoactive Drug
articipants assigned to this arm will receive dopamine as the first-line vasoactive drug for the treatment of cardiogenic shock. The drug will be initiated and titrated according to the protocol-defined dosing algorithm, with adjustments based on hemodynamic response, laboratory values, and clinical status. If participants were receiving vasoactive agents before randomization, dopamine will be started at an equivalent protocol-defined dose, and other agents will be tapered as clinically appropriate. All treatment and monitoring will follow current clinical guidelines for cardiogenic shock.
Related Therapeutic Areas
Sponsors
Leads: Chonnam National University Hospital

This content was sourced from clinicaltrials.gov